| Mrs Danielle Brandy Webb, LCSW,CADC | |
|
4839 W 47th St, Chicago, IL 60638-2039 | |
| (773) 735-2345 | |
| (773) 735-4025 |
| Full Name | Mrs Danielle Brandy Webb |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 4839 W 47th St, Chicago, Illinois |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003162520 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YA0400X | Counselor - Addiction (substance Use Disorder) | 26083 (Illinois) | Secondary |
| 1041C0700X | Social Worker - Clinical | 149.015085 (Illinois) | Primary |
| Entity Name | Access Community Health Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982783692 PECOS PAC ID: 9537076112 Enrollment ID: O20031204000985 |
News Archive
UnitedHealth Group today reported third quarter results, including strong revenue growth in both its Health Benefits and Health Services business groups. Third quarter 2010 net earnings were $1.14 per share. Key performance metrics and costs were in line with or better than Company expectations.
Science and industry are collaborating to develop future pharmaceuticals for treating chronic inflammatory diseases. The medicines will combat immunological processes that have gone wrong.
GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira(TM) (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
WideMed, a leading company engaged in the research, development and sale of innovative products for the growing bio-medical signal diagnostics and treatment market, announced today that the U.S. Food and Drug Administration has granted its home sleep monitoring device, Morpheus Ox, clearance to market in the United States for cardiac patient population.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Danielle Brandy Webb, LCSW,CADC 600 W Fulton St, Chicago, IL 60661-1259 Ph: (312) 526-2200 | Mrs Danielle Brandy Webb, LCSW,CADC 4839 W 47th St, Chicago, IL 60638-2039 Ph: (773) 735-2345 |
News Archive
UnitedHealth Group today reported third quarter results, including strong revenue growth in both its Health Benefits and Health Services business groups. Third quarter 2010 net earnings were $1.14 per share. Key performance metrics and costs were in line with or better than Company expectations.
Science and industry are collaborating to develop future pharmaceuticals for treating chronic inflammatory diseases. The medicines will combat immunological processes that have gone wrong.
GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira(TM) (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
WideMed, a leading company engaged in the research, development and sale of innovative products for the growing bio-medical signal diagnostics and treatment market, announced today that the U.S. Food and Drug Administration has granted its home sleep monitoring device, Morpheus Ox, clearance to market in the United States for cardiac patient population.
› Verified 7 days ago